Navigation Links
Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry

Strengthens DBI's Portfolio of Technologies for Enabling Faster, Easier Quantification of Protein Biomarkers in Translational Medicine and Adaptive

Clinical Trials

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Biomarkers Inc (DBI), a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the company's PATH(R) technology has been awarded United States Patent 7,297,497 by the U.S. Patent and Trademark Office. The patent applies to a novel, ultra-thin nitrocellulose surface chemistry that enables the detection of low-abundance proteins. This technology is integrated into DBI's AVANTRA(TM)Q400 Biomarker Workstation, a new, easy-to-use, immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in the lab or directly at a clinical trial site.

Protein microarray glass slides utilizing the PATH(R) technology are also available from leading life science consumable suppliers to enable researchers to perform ultra sensitive assays including sandwich immunoassays, capture immunoassays, protein profiling, and protein characterization.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Roger Dowd, CEO and President of DBI. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH(R) surface chemistry to be far superior to other commercially available protein-array surfaces."

The AVANTRA(TM)Q400 Biomarker Workstation, DBI's flagship product, is commercially available with various protein biomarker content including "off-the-shelf" multiplex biomarker panels for oncology, immunology, and cardiology, along with custom content defined by the Company's collaborators.

About Decision Biomarkers Inc

Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving the widespread adoption of protein biomarker analysis with the first automated, multiplex immunoassay system that can be used in real-time by virtually anyone, anywhere in drug development, clinical trials and diagnostics.

Copyright (C) 2007 Decision Biomarkers Inc. All rights reserved.

SOURCE Decision Biomarkers Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Ingenuity Systems Joins Biomarkers Consortium
10. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
11. Mirus Bio Awarded Grants & Contracts of Over $5 Million
Post Your Comments:
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):